The McCAVE Trial : Vanucizumab plus mFOLFOX-6 Versus Bevacizumab plus mFOLFOX-6 in Patients with Previously Untreated Metastatic Colorectal Carcinoma (mCRC)
Citation
Bendell , J C , Sauri , T , Gracian , A C , Alvarez , R , Lopez-Lopez , C , Garcia-Alfonso , P , Hussein , M , Limon Miron , M-L , Cervantes , A , Montagut , C , Santos Vivas , C , Bessudo , A , Plezia , P , Moons , V , Andel , J , Bennouna , J , van der Westhuizen , A , Samuel , L , Rossomanno , S , Boetsch , C , Lahr , A , Franjkovic , I , Heil , F , Lechner , K , Krieter , O & Hurwitz , H 2020 , ' The McCAVE Trial : Vanucizumab plus mFOLFOX-6 Versus Bevacizumab plus mFOLFOX-6 in Patients with Previously Untreated Metastatic Colorectal Carcinoma (mCRC) ' , Oncologist , vol. 25 , no. 3 , pp. e451-e459 . https://doi.org/10.1634/theoncologist.2019-0291
Rights
The article has been published under the Creative Commons licence - CC BY-NC-ND - https://creativecommons.org/licenses/by-nc-nd/4.0/